User profiles for Christian Lunetta
 | "christian lunetta"IRCCS Istituti Clinici Scientifici Maugeri Milano Verified email at icsmaugeri.it Cited by 7889 |
Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis
…, M Brunetti, S Arcuti, R Capozzo, C Zecca, C Lunetta… - Nature …, 2016 - nature.com
To elucidate the genetic architecture of amyotrophic lateral sclerosis (ALS) and find
associated loci, we assembled a custom imputation reference panel from whole-genome-sequenced …
associated loci, we assembled a custom imputation reference panel from whole-genome-sequenced …
[PDF][PDF] Genome-wide analyses identify KIF5A as a novel ALS gene
To identify novel genes associated with ALS, we undertook two lines of investigation. We
carried out a genome-wide association study comparing 20,806 ALS cases and 59,804 controls…
carried out a genome-wide association study comparing 20,806 ALS cases and 59,804 controls…
[HTML][HTML] Polymeric biomaterials for 3D printing in medicine: An overview
Three-dimensional (3D) printing is becoming a booming technology to fabricate scaffolds,
orthoses, and prosthetic devices for tissue engineering, regenerative medicine, and …
orthoses, and prosthetic devices for tissue engineering, regenerative medicine, and …
Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72
A large hexanucleotide (GGGGCC) repeat expansion in the first intron of C9ORF72, a gene
located on chromosome 9p21, has been recently reported to be responsible for ∼40% of …
located on chromosome 9p21, has been recently reported to be responsible for ∼40% of …
Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial
…, J Gamez, M Salvado, C Lunetta… - … Lateral Sclerosis and …, 2020 - Taylor & Francis
Objective: To assess masitinib in the treatment of ALS. Methods: Double-blind study, randomly
assigning 394 patients (1:1:1) to receive riluzole (100 mg/d) plus placebo or masitinib at …
assigning 394 patients (1:1:1) to receive riluzole (100 mg/d) plus placebo or masitinib at …
Burden, depression, and anxiety in caregivers of people with amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative disease
caused by the degeneration of motor neurons. The burden for ALS caregivers is quite high. …
caused by the degeneration of motor neurons. The burden for ALS caregivers is quite high. …
Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis
…, G Logroscino, FO Logullo, D Loi, C Lunetta… - Annals of …, 2019 - Wiley Online Library
Objective To identify shared polygenic risk and causal associations in amyotrophic lateral
sclerosis (ALS). Methods Linkage disequilibrium score regression and Mendelian …
sclerosis (ALS). Methods Linkage disequilibrium score regression and Mendelian …
[HTML][HTML] Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells
…, M Monteforte, V Torri, L Paris, G Bazzoni, C Lunetta… - PloS one, 2011 - journals.plos.org
Background Amyotrophic lateral sclerosis (ALS) is a fatal progressive motor neuron disease,
for which there are still no diagnostic/prognostic test and therapy. Specific molecular …
for which there are still no diagnostic/prognostic test and therapy. Specific molecular …
Physical activity and amyotrophic lateral sclerosis: A European population‐based case–control study
Objective To assess whether physical activity is a risk factor for amyotrophic lateral sclerosis
(ALS). Methods From February 2008 to April 2012, 652 patients with ALS from European …
(ALS). Methods From February 2008 to April 2012, 652 patients with ALS from European …
[HTML][HTML] Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis
…, N Fini, G Gianferrari, M Pinti, C Lunetta… - Nature …, 2023 - nature.com
In preclinical studies rapamycin was found to target neuroinflammation, by expanding
regulatory T cells, and affecting autophagy, two pillars of amyotrophic lateral sclerosis (ALS) …
regulatory T cells, and affecting autophagy, two pillars of amyotrophic lateral sclerosis (ALS) …
